GLPwatch
Glucagon-Like Peptide 1 Receptor Agonists (GLP1RA) and Sodium-glucose co-transporter-2 inhibitors (SGLT2i): Making a pragmatic choice in diabetes management.
J Pak Med Assoc · 2022
Last updated 2026-05-28GLP-1 receptor agonists and SGLT2 inhibitors are two types of diabetes medications that help lower blood sugar and reduce cardiovascular risks. Both drug classes can be used together, but their specific benefits and drawbacks are still debated. This article compares the two to guide doctors in making informed prescription choices.
AI summary of the abstract below.
| Journal | J Pak Med Assoc, 2022 |
|---|---|
| Citations | 3 |
| Relative citation ratio | 0.36 |
| NIH percentile | 22 |
| Molecules | — |
| Conditions studied | Type 2 Diabetes |
Abstract
The availability of newer glucose-lowering drugs has created opportunities for comprehensive diabetes care. Two classes of drugs, GLP1RA (glucagon-like peptide 1 receptor agonists), and SGLT2i (sodium glucose cotransporter 2 inhibitors) have demonstrated their efficacy in glucose control as well as cardiovascular risk reduction. While both can be used together, there is an ongoing debate regarding their relative advantages and limitations. We present a clinical perspective to compare and control these two classes of drugs, and promote rational prescription in diabetes praxis.
Verbatim abstract via PubMed 35713074 ↗